Oxybutynin exerts antispasmodic actions on the bladder, relieving the uncomfortable symptoms of overactive bladder, including urinary urgency and frequency
Licence Info
Oxybutynin transdermal patches are used to treat an overactive bladder (a condition in which the bladder muscles contract uncontrollably and cause frequent urination, urgent
It comes in 2 strengths: 2
diarrhoea, vomiting
2p Community Planning & Preservation Commission Meeting
Food and Drug Administration (FDA) and is indicated for patients with overactive bladder or symptoms of detrusor
9 mg of
Oxybutynin is used to treat symptoms of an overactive bladder, such as incontinence (loss of bladder control) or a frequent need to urinate
diarrhea, constipation
For a full list of excipients, see section 6
1
Initially 5 mg 2–3 times a day, increased if necessary up to 5 mg 4 times a day
Oxybutynin hydrochloride 5mg/5ml oral solution is supplied in bottles containing 100ml and
It is readily soluble in water and acids, but relatively insoluble in alkalis
Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic agents such as oxybutynin
Oxybutynin Tablets can be used in
5mg of oxybutynin in a 5ml spoonful
The SPC for oxybutynin states that the adverse effects of oxybutynin were mainly due to its anticholinergic effects, with dry mouth the most commonly reported
It works by relaxing the muscles of the bladder and stops sudden muscle contractions (spasms)
Se
Oxybutynin transdermal patch (Kentera®) is accepted for restricted use within NHS Scotland for the treatment of urge incontinence and/or increased urinary frequency and urgency in patients with unstable bladder, restricted to patients who derive clinical benefit from oral oxybutinin but who experience
View Summary of Product Characteristics (SmPC - Oxybutynin hydrochloride 5mg Tablets) Last updated on this site: 21 Aug 2023
2